On January 5, 2010, Silence Therapeutics completed its merger with Intradigm. A new website for the merged company is under development. In the meantime, please visit www.silence-therapeutics.com.
SCIENCE OF RNAi
Paradigm Advantages
Existing Paradigm |
siRNA Paradigm |
||
| Drugs/MOA | Small molecules, MoAb/Antagonists | siRNAs in a delivery vehicle/Silencing | |
| Targets | Mainly extracellular targets (Abs) | All targets | |
| Selectivity and Potency |
Usually low (small molecules) | Highly selective and potent | |
| Time to lead ID & Optimization |
Long (several years) | Short (few months) | |
| Risk | Usually high(small molecules) | Low (following POC of delivery vehicle) |